EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report

by Xinyu von Buttlar, MD, MS, Joshua E. Reuss, MD, Stephen V. Liu, MD, Chul Kim, MD, MPH
Published 2021-06-01

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC

by Joshua E. Reuss, MD, Emily Brigham, MD, MHS, Kevin J. Psoter, PhD, Khinh Ranh Voong, MD, Bairavi Shankar, BS, David S. Ettinger, MD, Kristen A. Marrone, MD, Christine L. Hann, MD, Benjamin Levy, MD, Josephine L. Feliciano, MD, Julie R. Brahmer, MD, David Feller-Kopman, MD, Andrew D. Lerner, MD, Hans Lee, MD, Lonny Yarmus, DO, Russell K. Hales, MD, Franco D’Alessio, MD, Sonye K. Danoff, MD, PhD, Patrick M. Forde, MBBCH, Karthik Suresh, MD, Jarushka Naidoo, MBBCH, MHS
Published 2021-10-01